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Abstract
Background: Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding
domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets.
Objective: To evaluate the activity and safety of apalutamide in patients with high-risk nonmetastatic
castration-resistant prostate cancer (nmCRPC).
Design, setting, and participants: We conducted a multicenter phase 2 study of nmCRPC patients with a
high risk for progression (prostate-speciﬁc antigen [PSA] 8 ng/ml or PSA doubling time [PSA DT] 10
mo).
Intervention: Patients received 240 mg/d apalutamide while continuing on androgen-deprivation ther-
apy.
Outcome measurements and statistical analysis: Primary end point was 12-wk PSA response (Prostate
Cancer Working Group 2 criteria). Secondary end points included safety, time to PSA progression (TTPP),
and metastasis-free survival (MFS).
Results and limitations: A total of 51 patients were enrolled; [20_TD$DIFF]four patients with metastatic disease were
excluded from the efﬁcacy analysis. Patient characteristics included median age, 71 yr; Eastern Coopera-
tive Oncology Group performance status 0 (76%); Gleason score 7 (57%); median PSA 10.7 ng/ml; and
PSA DT 10 mo (45%). At median follow-up of 28.0 mo, 18 patients (35%) remained in the study. Overall,
89% of patients had 50% PSA decline at 12 wk. Median TTPP was 24.0 mo (95% conﬁdence interval [CI],
16.3mo–not reached [NR]); medianMFSwas NR (95% CI, 33.4mo–NR). Most of the patients discontinued
study treatment (n = 33) due to disease progression (n = 11 [22%]) or adverse events (AEs) (n = 9 [18%]).
The most common AE was fatigue (any grade, n = 31 [61%]) although grade 3 fatigue was uncommon
(n = 2 [4%]). These represent the ﬁrst apalutamide nmCRPC patient clinical data.
Conclusions: In high-risk nmCRPC patients, apalutamide was safe with robust activity based on durable
PSA responses and disease control.
Patient summary: Antitumor activity and the safety of apalutamide in patients with nonmetastatic
castration-resistant prostate cancer support continued development in this setting.
Trial registration: ClinicalTrials.gov identiﬁer NCT01171898
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Androgen-deprivation therapy (ADT) is the standard first-
line treatment for patients with metastatic prostate cancer
(PCa) and a routine part of management for manymen with
nonmetastatic PCa. Initial ADT achieves responses in nearly
all patients, although most patients progress to castration-
resistant disease within a few years [1]. In men with
nonmetastatic castration-resistant prostate cancer
(nmCRPC), higher prostate-specific antigen (PSA) and
shorter PSA doubling time (PSA DT) are associated with
high risk for metastases and death [2–4]. Examining
patients at regular intervals is important because patients
with a short PSA DT are often found with occult metastases.
National Comprehensive Cancer Network PCa clinical
practice guidelines recommend more frequent bone imag-
ing for patients with a PSA DT 8 mo [5]. To date, there are
no approved treatments for nmCRPC.
Apalutamide is a potent antagonist of the androgen
receptor (AR) in development for the treatment of menwith
CRPC as well as earlier disease including localized PCa and
metastatic hormone-sensitive PCa [6]. Apalutamide selec-
tively binds to the ligand-binding domain of AR and blocks
AR nuclear translocation or binding to androgen response
elements. Unlike bicalutamide, apalutamide antagonized
AR-mediated signaling in AR overexpressing human CRPC
cell lines [7]. In mice bearing human CRPC xenografts,
apalutamide produced dose-dependent tumor regressions
superior to those achieved with bicalutamide or enzaluta-
mide [6].
On the basis of these promising preclinical results, a first-
in-human phase 1/2 study was conducted (ARN-509-001)
in patients with CRPC. The 18F-fluoro-a-dihydrotestoster-
one positron emission tomography/computed tomography
imaging analysis in 16 patients with metastatic CRPC
(mCRPC) indicated an optimal biologic dose of 240 mg/d of
apalutamide; the phase 1 portion of the study in 30 mCRPC
patients determined that a phase 2 dose of 240 mg/d was
safe and well tolerated [8]. The phase 2 portion of the study
evaluates apalutamide activity in three distinct patient
cohorts: nmCRPC, abiraterone acetate–naive mCRPC, and
post–abiraterone acetate mCRPC. We report the phase
2 results for patients in the nmCRPC cohort.
2. Patients and methods
ARN-509-001 (NCT01171898) is a phase 1/2 multicenter open-label
study. Phase 1 was completed in May 2012 and the results were
published [8]. Patients were enrolled into the phase 2 expansion cohorts
from November 2011 to June 2012, and the study is ongoing. The review
boards at all participating institutions approved the study that was
conducted according to the Declaration of Helsinki, the International
Conference on [21_TD$DIFF]Harmonisation, and the Guidelines for Good Clinical
Practice. All patients gave written informed consent.
2.1. Patients
All patients had histologically or cytologically conﬁrmed PCa and had
received ongoing ADTwith a gonadotropin-releasing hormone analog or
inhibitor, or orchiectomy (ie, surgical or medical castration). Patients inthe nmCRPC cohort had no radiographic evidence of distant metastases
(central nervous system [CNS], vertebral, or meningeal) as determined
by central review (pelvic lymph nodes <3 cm below the iliac bifurcation
were allowed). They met the following inclusion criteria: castrate levels
of serum testosterone 50 ng/dl within 4 wk of study enrollment, an
Eastern Cooperative Oncology Group performance status of 0–1, a life
expectancy 3 mo, a corrected QT interval 450 ms, and adequate
cardiac, renal, hepatic, and bone marrow function. The patients had a
high risk for developing metastases, deﬁned as either a PSA value 8 ng/
ml obtained within 3mo prior to enrollment or [22_TD$DIFF]PSA DT [8_TD$DIFF]10mo. Patients
were excluded if they had been treated previously with enzalutamide,
abiraterone acetate, or ketoconazole, or had a history of seizures or
conditions that predispose to seizures or concurrent treatment with
medications known to have seizure potential.
2.2. Study design
Patients were enrolled in three cohorts: nmCRPC, chemotherapy/
abiraterone acetate–naivemCRPC, andmCRPC post–abiraterone acetate,
as shown in Figure 1 [8]. This study focuses on the high-risk nmCRPC
expansion cohort. Patients received apalutamide 240 mg/d based on the
biologically efﬁcacious dose established in the phase 1 study [8]. Patients
with nmCRPC received continuous daily dosing until disease progression
deﬁned as evidence of PSA progression and radiographic progression as
described below, or clinical progression alone (skeletal-related event or
pain progression requiring intervention). Dose modiﬁcations (eg, short
treatment breaks or dose reduction) were allowed in case of treatment-
related adverse events (AEs).
2.3. End points
PSA response was assessed using the Prostate Cancer Working Group 2
(PCWG2) criteria [9]. Imaging evaluations were performed every 16 wk.
The primary end point was the posttreatment percentage change in PSA
relative to baseline at 12 wk (or earlier for those who discontinued
therapy) and maximal change at any time on the study. The secondary
efﬁcacy end points included time to PSA progression (TTPP), measured
from the start of treatment until the criteria for PSA progression were
met, according to the modiﬁed PCWG2 (25% and >2 ng/ml above PSA
nadir conﬁrmed 3 wk later or >2 ng/ml above baseline PSA after
12 wk), and metastasis-free survival (MFS), measured from the start of
treatment until new metastatic lesions were seen on computed
tomography/magnetic resonance imaging scans by modiﬁed Response
Evaluation Criteria in Solid Tumors [10] and/or 99m-technetium-
methylene diphosphate bone scans (after repeat imaging 6 wk later),
independently veriﬁed by central imaging.
2.4. Safety
Safety was assessed on an ongoing basis from the ﬁrst dose until 30 d
after the last dose or until the resolution of any drug-related AE.
2.5. Statistical analysis
The sample size was based primarily on clinical judgment. A combined
12-wk PSA response rate of at least 20% in the nmCRPC cohort was
considered of clinical interest to warrant further development of
apalutamide in nmCRPC. If 22 of 70 patients (including a chemothera-
py/abiraterone acetate cohort not described here) achieved a 12-wk PSA
response of at least 50%, the lower exact 95% conﬁdence interval (CI) was
20.9% with the upper limit of 43.6%. All patients who received at least
one dose of apalutamide were included in the efﬁcacy (excluding four
patients who had baseline metastases) and safety analyses. Summary
statistics were reported for demographics, baseline characteristics, AEs,
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Fig. 1 – Study design[1_TD$DIFF]. Progression-free survival not analyzed for the nonmetastatic castration-resistant prostate cancer (nmCRPC) cohort and for four
patients with metastatic disease not included in the nmCRPC efficacy analysis.
AA = abiraterone acetate; CRPC = castration-resistant prostate cancer; mCRPC =metastatic [2_TD$DIFF] castration-resistant prostate cancer; PSA = prostate-specific
antigen.
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12 wk relative to baseline and the maximal change in PSA at any time on
the study relative to baseline are presented in waterfall plots andTable 1 – Patient characteristics
High-risk nmCRPC
n 51
Age, yr, median (range) 71 (51–88)
ECOG PS, n (%)
0 39 (76)
1 12 (24)
Gleason score at initial diagnosis, n (%)
7 29 (57)
8–10 18 (35)
Not available 4 (8)
Time since initial diagnosis, mo, median (range) 119.5 (20–238)
Baseline PSA, ng/ml, median (range) 10.7 (0.5–201.7)
High-risk deﬁnition, n (%)
PSA 8 ng/ml, median (range) 21 (41)
PSA DT 10 mo 23 (45)
Both criteria 7 (14)
Prior hormonal therapy, n (%)
LHRH 46 (90)*
Antiandrogeny 41 (80)
Bicalutamide 41 (80)
Flutamide 6 (12)
Nilutamide 8 (16)
ECOG PS = Eastern Cooperative Oncology Group performance status;
LHRH = luteinizing hormone-releasing hormone; nmCRPC = nonmetastatic
castration-resistant prostate cancer; PSA = prostate-speciﬁc antigen; PSA
DT = prostate-speciﬁc antigen doubling time.
* Three patients had an orchiectomy; two patients did not receive ongoing
hormonal therapy because serum testosterone was at castrate levels at
screening and remained at castrate levels without LHRH.
y Patients may have been treated with more than one antiandrogen.descriptively summarized. The Kaplan-Meier method was used to
estimate the median time to events and 95% CIs.
3. Results
3.1. Patients
The high-risk nmCRPC cohort enrolled 51 patients from
November 2011 to June 2012. The data cut-off for database
lock and primary analysis was December 31, 2014. Median
patient age was 71 yr (range: 51–88); most patients were
white (47 of 51 [92%]). Median baseline PSA was 10.7 ng/ml
(Table 1). Patients were enrolled with a PSA 8 ng/ml (21 of
51 [41%]) or PSA DT 10 mo (23 of 51 [45%]), with seven
patients having both criteria met (14%). Most patients (80%)
had received prior treatment with a first-generation anti-
androgen (ie, bicalutamide, flutamide, or nilutamide)
(Table 1). Four patients had metastatic disease and were
excluded from the efficacy analysis because they later were
determined to have metastases on their screening scans
(Fig. 2). At a median follow-up of 28.0 mo, 18 of 51 patients
(35%) remained in the study.Most whowent off the study did
so either for disease progression (11 of 51 [22%]) or AEs (9 of
51 [18%]). Themediantreatmentdurationwas26.9mo(range:
<1–37.8).
3.2. Prostate-specific antigen outcome
The median change in PSA from baseline to week 12, per
PCWG2 criteria, was 85% (range: 99.9 to 52.2). The
median maximal change in PSA from baseline to any point
during the study was 93% (range: –99.9 to 47.5). This
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Fig. 2 – Patient disposition.
PSA = prostate-specific antigen [14_TD$DIFF].
*Patients may have discontinued due to more than one type of progression.
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baseline) at 12 wk of 89% (Table 2 and Fig. 3A). Themaximal
PSA response (maximal percentage reduction [50%] after
baseline at any time) was reported in 94% of patients
(Table 2 and Fig. 3B).
3.3. Secondary end points
A total of 53% of patients (25 of 47) with nmCRPC had PSA
progression while on the study. At a median follow-up of
28.0 mo, the median TTPP and MFS were 24 mo (95% CI,
16.3 mo–not reached [NR]) and NR (95% CI, 33.4 mo–NR),
respectively (Table 2 and Fig. 4).Table 2 – Efficacy outcomes
High-risk nmCRPC (n = 47)*
PSA response, wk, n (%)y
12 42/47 (89)
24 40/47 (85)
36 22/47 (47)
Maximal PSA response, n (%)z 44/47 (94)
Median MFS, mo (95% CI) NR (33.4–NR)
Median time to PSA progression,
mo (95% CI)
24.0 (16.3–NR)
CI = conﬁdence interval; MFS = metastasis-free survival; nmCRPC =
nonmetastatic castration-resistant prostate cancer; NR = not reached;
PSA = prostate-speciﬁc antigen.
* Four patients with metastatic disease at baseline were not included.
y A50% decline in PSA frombaseline from Prostate CancerWorkingGroup 2.
z Maximal PSA response is themaximal percentage reduction after baseline at
any time point.3.4. Safety
The most common treatment-emergent adverse events
(TEAEs) regardless of relationship to the study drug were
fatigue (61%), diarrhea (43%), and nausea (39%) (Table 3).
Most TEAEs were grade 1 or 2. Grade 3 TEAEs reported in
more than one patient each were fatigue (n = 2 [4%]),
hypertension (n = 2 [4%]), and malignant melanoma
(n = 2 [4%]). The most common TEAEs related to study
treatment were fatigue (45%), diarrhea (29%), and nausea
(25%); no serious TEAEs were considered related to study
treatment. No seizures, amnesia, or visual disturbance were
reported. Headache and dizziness were reported in seven
patients (14%) and six patients (12%), respectively. TEAEs of
a fall (all grade 1 or 2) were reported in five patients (10%)
with a resultant grade 1 contusion in one patient. Another
patient had several TEAEs (all grade 1 or 2) including a
contusion secondary to a fall not reported as an AE. TEAEs
that led to permanent treatment discontinuation were
fatigue (n = 2 [4%]); abdominal adhesions, bone marrow
tumor cell infiltration, brain cancer, colorectal cancer,
decreased appetite, drug hypersensitivity, dysphagia,
esophageal cancer, nerve root compression, and macular
rash (n = 1 [2% each]); it was possible for patients to
experience more than one TEAE leading to treatment
discontinuation. TEAEs that led to dose modification were
fatigue (n = 2 [4%]); choking, contusion, erythematous rash,
and vomiting (n = 1 [2% each]). TEAEs that led to dose
interruption were observed in 15 patients (29%); the only
TEAE leading to dose interruption that was observed in
more than one patient was diarrhea in two patients (4%).
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Fig. 3 – Waterfall plot for (A) 12-wk prostate-specific antigen (PSA) response and (B) maximal PSA response at any time.
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In this phase 2 study of apalutamide, we confirm the safety
and tolerability profile of the previously established
biologically efficacious dose of 240 mg/d [8] in the nmCRPC
cohort. This study used several measures to determine the
antitumor activity of apalutamide including declines in PSA
level per PCWG2 criteria [9], TTPP, and MFS. With
apalutamide treatment, 89% of patients (42 of 47) with
high-risk nmCRPC experienced a 50% decline in PSA level
after 12 wk on the study, with a maximal PSA response
(50% after baseline at any time) reported in 94% of patients
(44 of 47). At 28.0 mo of follow-up, the median TTPP and
MFS were 24 mo and NR, respectively. Grade 3 and 4 TEAEs
were infrequent. The most common treatment-related
TEAEs were fatigue (45%), diarrhea (29%), and nausea
(25%); these were mostly grade 1 and 2. Collectively, these
data support the continued clinical development ofapalutamide in future efficacy and safety studies of men
with nmCRPC.
The most common grade 3 and 4 TEAEs were fatigue
(n = 2 [4%]), hypertension (n = 2 [4%]), and malignant
melanoma (n = 2 [4%]). Grade 3 secondary malignant
melanomas were observed after 2.5 yr in one patient and
1 yr in a second. They were considered unrelated to the
study drug and were not associated with dose reductions or
interruptions. The most common treatment-related TEAEs
were fatigue (45%), diarrhea (29%), and nausea (25%); these
were mostly grade 1 and 2. Overall, apalutamide was safe
and well tolerated.
Risk of seizures has been identified with AR antagonists
as a class and is thought to be mediated via CNS-based g-
aminobutyric acid A receptors [11]; this represents an
exclusion criterion in studies of enzalutamide [12–14] as in
the current study with apalutamide. No seizures were
reported in the current study, consistent with the safety
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Fig. 4 – Secondary end points: (A) Time to prostate-specific antigen progression[15_TD$DIFF] (PSA); (B) metastasis-free survival.
CI = confidence interval; NR = not reached[4_TD$DIFF].
E U RO P E AN URO L OG Y 7 0 ( 2 0 1 6 ) 9 6 3 – 9 7 0968data from the phase 1 clinical trial of apalutamide [8]. Falls
have been reported to be more frequently observed with
enzalutamide compared with placebo [12] and may also
represent an AR antagonist class risk related to CNS effects.
In the current study, five patients experienced grade 1 and
2 falls, but these falls were not reported as serious and did
not result in discontinuation of the study drug.
Safe and effective treatment to delay or prevent the
development of metastatic disease in nmCRPC is an
important unmet medical need. The results of phase
3 metastasis prevention studies of zoledronic acid, deno-
sumab, clodronic acid, and atrasentan did not support the
regulatory approval of these agents for treatment of
patients with nmCRPC [15–18]. The results of these phase
3 studies, however, have helped define the natural history ofnmCRPC and facilitate the description of high risk based on
PSA kinetics.
Strengths of this phase 2 study include the multicenter
design and relatively long follow-up interval. The pre-
specified definition of the high-risk nmCRPC cohort is also a
substantial strength. Limitations include the nonrandom-
ized nature of the study and the modest sample size.
The results of this phase 2 study informed the design of
the global SPARTAN study (NCT01946204). SPARTAN is a
multicenter double-blind placebo-controlled phase 3 trial
to evaluate the efficacy and safety of apalutamide in
patients with nmCRPC at high risk for progression, defined
as a PSA DT 10 mo. The primary end point is MFS.
Key secondary end points are overall survival, time to
symptomatic progression, time to initiation of cytotoxic
Table 3 – Treatment-emergent adverse events occurring in I15%
of patients
High-risk nmCRPC (n = 51)
All grades Grade 3*
No. of patients with 1 TEAE 51 (100) 21 (41)
No. of patients with a serious
TEAE
16 (31) 12 (24)
TEAEs, n (%) All grades Grade 3*
Fatigue 31 (61) 2 (4)
Diarrhea 22 (43) 1 (2)
Nausea 20 (39) 0
Arthralgia 11 (22) 1 (2)
Back pain 11 (22) 0
Dysgeusia 11 (22) 0
Hypothyroidism 11 (22) 0
Hot ﬂush 10 (20) 0
Pain in extremity 10 (20) 1 (2)
Cough 10 (20) 0
Abdominal pain 9 (18) 0
Decreased weight 9 (18) 0
Pollakiuria 9 (18) 0
Constipation 8 (16) 0
Nasopharyngitis 8 (16) 0
Hematuria 8 (16) 0
Upper respiratory infection 8 (16) 0
nmCRPC = nonmetastatic castration-resistant prostate cancer; TEAE =
treatment-emergent adverse event.
* Listed grade 3 adverse events are those with an overall incidence 15%.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 9 6 3 – 9 7 0 969chemotherapy, radiographic progression-free survival, and
time to metastasis. SPARTAN is ongoing [19]. Additional
phase 3 trials in the high-risk nmCRPC patient population
are also under way for the AR inhibitors enzalutamide
(NCT02003924 [20]) and ODM-201 (NCT02200614 [21]).
In the absence of comparative studies of apalutamide,
enzalutamide, and ODM-201, it is not possible to draw
conclusions about the relative efficacy and safety of the
different AR antagonists in the treatment of patients with
nmCRPC. Nevertheless, AR antagonists appear promising in
exerting clinical benefit in the nmCRPC population based on
the results of this study as well as those of the STRIVE study
[13].
Overall, apalutamide was well tolerated in this cohort of
patients with high-risk nmCRPC, with a safety profile
consistent with the previous phase 1 study. No serious
TEAEs or seizures were reported.
5. Conclusions
Apalutamide was safe and well tolerated in patients with
high-risk nmCRPC in the phase 2 portion of the study.
Apalutamide exhibited robust activity in patients with
high-risk nmCRPC based on durable PSA responses and
disease control. These results support further clinical
development of apalutamide in nmCRPC.
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